Drug Profile

Research programme: Anti-MUC16 x CD3 bispecific T-cell engagers - iBio

Alternative Names: Anti MUC16 x CD3 bispecific antibodies - iBio

Latest Information Update: 16 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator iBio Inc
Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies; Recombinant fusion proteins
Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

09 Nov 2023 iBio Research programme: Anti-MUC16 x CD3 bispecific T-cell engagers - iBio is available for licensing as of 09 Nov 2023. https://ibioinc.com/about/
01 Nov 2023 Early research in Cancer in USA (Parenteral)
03 Jan 2023 iBio has patent protection for "epitope-steering AI-engine" technology (US 11 545 238) in USA (iBio website, November 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com